Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

Abstract SARS-CoV-2 Omicron subvariants BA. 2.12. 1 and BA. 4/5 have surged notably to
become dominant in the United States and South Africa, respectively,. These new …

The COVID-19 pandemic has had widespread effects across the globe, and its causative
agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …

Abstract The SARS-CoV-2 Delta variant is currently the dominant circulating strain in the
world. Uncovering the structural basis of the enhanced transmission and altered immune …

Neutralizing antibodies (nAbs) elicited against the receptor binding site (RBS) of the spike
protein of wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are …

Background With the continuation of the COVID-19 pandemic, some COVID-19 patients
have become reinfected with the virus. Viral gene sequencing has found that some of these …

Vaccination of the global population against COVID-19 is a great scientific, logistical, and
moral challenge. Despite the rapid development and authorization of several full-length …

Highlights•Structural biology plays a vital role in SARS-CoV-2 vaccine and treatment.•High-
resolution structures of SARS-CoV-2 proteins and complexes have been obtained.•In situ …